Ascelia Pharma presented its Hepatic Impairment Study data, which was showcased at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting in Valencia, Spain, on June 13-16, 2023. The company also held a Q&A session to discuss liver imaging and unmet needs for patients suffering from severe kidney impairment.
The Hepatic Impairment Study showed that Ascelia Pharma's contrast agent Orviglance is well-tolerated by patients with hepatic impairment. There were no significant safety concerns identified during the study, confirming that Orviglance can be used in patients with any degree of hepatic impairment. Additionally, Orviglance has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). During ESGAR 2023, Ascelia Pharma hosted a Q&A session featuring two experts in liver imaging who discussed the role of liver imaging in cancer care, clinical practice for patients with severe kidney impairment, and trends ahead. Orviglance is the first contrast agent developed for use in liver magnetic resonance imaging (MRI) in patients with severely impaired kidney function. The